ABBVx uses a multi-chain issuance model on Solana SPL and ERC-20 to ensure compatibility with supported wallets, trading platforms, and DeFi applications.

ABBVx does not grant ownership of AbbVie shares or voting rights; it tracks price performance and enables on-chain transferability and blockchain-native settlement.

This tokenized instrument serves as an example of the broader shift toward real-world asset tokenization, marrying traditional equities with digital asset infrastructure.

The product is part of a wider trend to connect traditional capital markets with regulated issuance structures backed by the underlying asset.

AbbVie Inc. underlies ABBVx, a global biopharmaceutical company formed in 2013 from the split of Abbott Laboratories, with a portfolio spanning immunology, oncology, neuroscience, and eye care.

A tokenized tracker certificate, ABBVx, provides blockchain-native economic exposure to AbbVie Inc. stock by issuing Solana SPL and ERC-20 tokens within the xStocks ecosystem.

The offering targets eligible crypto market participants seeking economic exposure to AbbVie's stock within digital wallets and DeFi ecosystems, positioning tokenized stocks as reference assets for blockchain instruments.

Investors should note that token holders do not own stock or governance rights; price exposure reflects AbbVie’s share performance and related pharmaceutical risks, plus potential blockchain and regulatory risks including custody, liquidity, and jurisdictional restrictions.